SAP Connected Health platform to shape clinical studies and delivery of new drugs, devices and care plan for lung and colorectal cancer patients
SINGAPORE, July 26, 2017 — SAP SE (NYSE: SAP) and the National Cancer Centre Singapore (NCCS) are today announcing a co-innovation project to help clinical research in Singapore. The SAP Connected Health platform, the first of its kind in Singapore, is targeted to integrate both structured and unstructured data such as clinical and genomic data, into a comprehensive platform supported by best-in-class analysis algorithms and visualization tools. This is aimed at providing researchers and physicians/oncologists with real actionable insights that can advance the treatment and care for cancer patients.
The SAP Connected Health platform, built on SAP HANA®, is an in-memory solution that opens access to the critical data held throughout the healthcare system, so healthcare providers and researchers should create new ideas and deliver the best outcomes for patients. NCCS will also use SAP Health for Clinical Research, patient insights option, part of SAP Health portfolio of solutions, which delivers real-time analysis and reporting that together lead to personalized treatment options.
The SAP Connected Health platform is expected to leverage the technological and infrastructural improvements in electronic health medical records as well as bio-molecular advances in comprehensive characterization and profiling in the molecular characteristics and biological components of patient tumour cells. This has led to a deluge of information that may be harvested for research and development (R&D) towards improving precise and effective delivery of cancer care.
The platform is similar to innovation projects that have been successfully implemented elsewhere, including at CancerLinQ LLC, a wholly owned non-profit subsidiary of the American Society of Clinical Oncology (ASCO) and Seoul University’s Bundang Hospital. The project leverages the global SAP Health team.
For this initiative, SAP Co-innovation Labs Singapore (SAP COIL) provided the project framework under which systems, infrastructure and the SAP Health platform were made available locally in Singapore to comply with data privacy concerns. SAP COIL’s global sponsors Cisco, NetApp, Intel, and VMware provided the dedicated environment for NCCS and SAP Health customer implementation teams to configure and customize the solution based on local requirements. NCCS provides knowledge and domain expertise into the R&D pathway for computational big-data tools to impact R&D in cancer and precision medicine. This R&D effort will be piloted in anonymized datasets of cancer patients comprising clinical parameters integrated with cutting edge molecular profiling (-omics) information.
SAP COIL has a mandate to facilitate co-innovation between SAP and partners and / or customers in the local eco-system. It is part of a global network of labs in 14 cities including Palo Alto, Newtown Square, Sao Paulo, Sao Leopoldo, Dresden, Walldorf, Zurich, Moscow, Johannesburg, Bangalore, Singapore, Shanghai, Seoul and Tokyo.
“Today marks a significant milestone in our collaboration on health initiatives with partners in Singapore, in line with SAP’s objectives of providing the best underlying technology to power tomorrow’s medical advancements. We’re confident that this collaboration with NCCS will help to improve connected care and precision medicine, and demonstrates clearly how Big Data can help to advance cancer treatments. By leveraging our experience in working with healthcare organizations throughout the world, Singapore stands to expand its capabilities in connected health technologies in a very meaningful way,” said Andy David, Director for Healthcare in the Asia Pacific region at SAP.
Dr Iain Tan, Senior Consultant Medical Oncologist at NCCS, said: “We seek to co-innovate this cutting-edge connected health platform to link up genomic and clinical data for R&D. This research prepares us to play a leading role as digital and computational platforms to empower us towards the future of data-informed healthcare decision making which we envision will be applied to our individual patients.”
# # #
About National Cancer Centre Singapore
National Cancer Centre Singapore (NCCS) provides a holistic and multidisciplinary approach to cancer treatment and patient care. We treat majority of the public sector oncology cases, and they are benefiting from the sub-specialisation of our clinical oncologists. NCCS is also accredited by the US-based Joint Commission International for its quality patient care and safety. To deliver among the best in cancer treatment and care, our clinicians work closely with our scientists who conduct robust cutting-edge clinical and translational research programmes which are internationally recognised. NCCS strives to be a global leading cancer centre, and shares its expertise and knowledge by offering training to local and overseas medical professionals. www.nccs.com.sg
As market leader in enterprise application software, SAP (NYSE: SAP) helps companies of all sizes and industries run better. From back office to boardroom, warehouse to storefront, desktop to mobile device – SAP empowers people and organizations to work together more efficiently and use business insight more effectively to stay ahead of the competition. SAP applications and services enable more than 355,000 business and public sector customers to operate profitably, adapt continuously, and grow sustainably. For more information, visit www.sap.com.
Any statements contained in this document that are not historical facts are forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to SAP are intended to identify such forward-looking statements. SAP undertakes no obligation to publicly update or revise any forward-looking statements. All forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from expectations. The factors that could affect SAP’s future financial results are discussed more fully in SAP’s filings with the U.S. Securities and Exchange Commission (“SEC”), including SAP’s most recent Annual Report on Form 20-F filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates.
© 2017 SAP SE. All rights reserved.